GlassScriptPhysician profile
Susan Damico
NPI 1508835059
$1,389.56
in general payments reported to CMS, 2019-2025
15 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $281 · 2022: $145 · 2023: $369 · 2024: $396 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.98 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $200.34 | 2023-2025 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $190.11 | 2023-2024 | Injectafer, Vanflyta, Enhertu |
| Cvrx, INC. | $144.91 | 2021 | |
| Mirati Therapeutics, INC. | $137.56 | 2023 | Krazati |
| Jazz Pharmaceuticals INC. | $104.26 | 2021 | |
| Gilead Sciences, INC. | $103.51 | 2021-2024 | Trodelvy |
| Emd Serono, INC. | $102.02 | 2022 | |
| Abbvie INC. | $88.24 | 2022-2025 | |
| Stemline Therapeutics INC. | $83.20 | 2023 | Orserdu |
| Novartis Pharmaceuticals Corporation | $64.96 | 2023-2024 | |
| Pfizer INC. | $53.95 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $49.22 | 2025 | Imfinzi |
| Janssen Biotech, INC. | $31.69 | 2021-2022 | |
| Seagen INC. | $18.23 | 2023 | Tukysa |
| Eisai INC. | $17.36 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Damico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.